C3 and breast cancer: Prompted by our earlier approaches to generate chemically engineered supramolecular multidomain protein/peptide complexes [7,18] and a supramolecular avidin photosensitizer that targets triple negative BC [20], avidin/biotin technology was used to obtain the bioconjugate (JM173)3-Avi-C3.